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Objective: We aimed to assess the therapeutic efﬁcacy of differentially modiﬁed soluble receptor for
advanced glycation end products (sRAGE) in vivo using vessel ultrasound sonography and to compare theKey words:
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sonography data with those from postmortem histomorphologic analyses to have a practical reference
for future clinical applications.
Methods: Vessel ultrasound sonography was performed in a sRAGE-treated rat carotid artery balloon
injury model at different time points after the surgery, and therapeutic efﬁcacy of different doses of
sRAGE produced in Chinese hamster ovary cells and with different N-glycoform modiﬁcations were
assessed.
Results: Vessel ultrasound sonography found that sRAGE produced in Chinese hamster ovary cells with
complex N-glycoform modiﬁcations is highly effective, and is consistent with our recent ﬁndings in the
same model assessed with histology. We also found that sonography is less sensitive than histology
when a higher dose of sRAGE is administered.
Conclusions: Sonograph results are consistent with those obtained from histology; that is, sRAGE
produced in Chinese hamster ovary cells has signiﬁcantly higher efﬁcacy than insect cell-originated
sRAGE cells.
Published by Elsevier GmbH. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).Introduction
Inﬂammation is a natural protective mechanism that resolves
infections and injuries of the target tissue.1 Failure to effectively
resolve the inﬂammation and return the affected tissue to homeo-
stasis leads to maladaptation and precipitation of pathophysiologic
consequences that often result in the development of chronic
maladies, including cardiovascular diseases and diabetic compli-
cations.2,3 It has been well established that injury-elicited inﬂam-
mation in the vasculature often causes excessive proliferation of
vascular smooth muscle cells within vessel walls and the subse-
quent expansion of the intima, leading to the eventual blockage of
the vessel.4–6 These remodeling processes are intensiﬁed espe-
cially in patients with diabetes. Although effective in combatingpen access article under the CC BY
ry of Cardiovascular Science,
alth, Baltimore, MD 21224neointima hyperplasia, current anti-inﬂammatory and antimitotic
drugs often display signiﬁcant side effects and toxicity that deem
systemic applications unfeasible, and their local delivery is
achieved via drug-eluting stents.7,8 Therapeutic reagents that can
be administered systemically stand the beneﬁt of providing alter-
native avenues for treating acute vascular injuries as well as
circumventing overall chronic inﬂammation in the vasculature.9
RAGE is a pattern recognition receptor that recognizes multiple
endogenous ligands and triggers innate and adaptive immune
responses.10–14 Signaling via RAGE has been associated with
vascular inﬂammation and implicated in the development of
cardiovascular diseases.15,16 Prior studies17,18 have shown that
administration of sRAGE can protect against injury-mediated
vascular inﬂammation and neointimal expansion by functioning
as a RAGE decoy. Such protection by sRAGE may also be extended
to other inﬂammatory conditions, including diabetic complications
and atherosclerosis.19,20 Our recent study21 demonstrated that N-
glycoform modiﬁcations of sRAGE modulate its bioactivity: com-
pared with sRAGE produced in insect Sf9 cells used in previous-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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low dose of sRAGE produced in Chinese hamster ovary cells
(sRAGECHO) (ie, 3 ng/g body weight) can substantially reduce
neointima growth and inﬂammation in a rat carotid balloon injury
model. These ﬁndings render sRAGECHO an attractive therapeutic
candidate with clinical potential.13,22
Although previous studies assessed how sRAGE treatment affected
neointimal growth via histomorphologic analyses of postmortem
vessel sections,17,18,21 direct assessment of sRAGE action in vivo has
not been performed. Vessel ultrasound sonography is a technique that
can be used noninvasively in clinical practice to monitor arterial
structure and function.23–25 To further validate sRAGE efﬁcacy to
suppress neointimal growth, and to provide a basis for future clinical
applications, we performed sonograph studies on carotid balloon
denudation-injured rats before histology and compared these results
with those observed in histomorphologic analyses. Such studies
render an independent assessment of sRAGECHO efﬁcacy in vivo,
and can validate its potential as a candidate therapeutic protein for
treating vascular injury and inﬂammation. The present study was an
extension of our previously published work.21Materials and Methods
Subjects
Male Wistar rats (400–450 g) were purchased from Charles
River Laboratories (Wilmington, Massachusetts) and maintained in
a vivarium fed the National Institute on Aging on ad libitum food
diet (NIH-07 mouse/rat diet; National Institutes of Health,
Bethesda, MD) with access to ﬁltered water. Each study group
contained 6 to 15 rats.
Carotid artery balloon denudation injury procedure
The surgical procedure and postsurgery care have been described
in detail,21 and have been in compliance with the National Institutes
of Health’s Guide for the Care and Use of Laboratory Animals (NIH
publication No. 3040-2, revised 1999), and with the institutional
Animal Care and Use Committee approved protocol.
Production and administration of sRAGE
Immediately following the surgery, rats were administered the
designated dose of sRAGE via intraperitoneal injection. Generation
of sRAGECHO, sRAGESf9, and sRAGECHO(N25T/N81T) expression
vectors, as well as puriﬁcation of sRAGE recombinant protein have
been described in detail.21
Vessel ultrasound sonography
Vessel ultrasound sonography was conducted on the 0 Day (ie,
surgery day, before surgery), and on the seventh and 14th day
postsurgery. Rats were sedated with isoﬂorane (2% in oxygen) via
facemasks, and put in the supine position. After shaving frontal neck
skin hair, a 40 MHz probe was used to scan the carotid arteries. An
M-mode tracing was recorded at 3 points in the long-axis view:
3 and 10 mm distal to the base, and 2 mm proximal to the
bifurcation. Each M-mode tracing included the whole vessel wall
thickness and lumen diameter. Vessel wall thickness was also
recorded alone, using a zoom-in function. A B-mode scan was
recorded at 2 mm proximal to the bifurcation. Each vessel was
measured 5 times. The vessel wall thickness and lumen diameter at
minimal and maximal points were measured using National Insti-
tutes of Health Image J software. The parameters from the non-
operated right carotid artery of the same rat were used as control.Tissue collection and histomorphologic analysis
Isolation of carotid vessels and histomorphologic analyses have
been described.21 In all analyses, parameters from the nonoper-
ated right side of the carotid artery of the same subjects were used
as the normal control relative to the balloon-injured left side of the
carotid artery.
Allocation concealment
Allocation concealment was applied to balloon denudation
surgery, sonographic studies, and histomorphologic analyses.
Investigators involved in the procedure were also blinded in
respect to sRAGE types and dose administered.
Statistical analysis
Numerical data are expressed as means (SEM). Sonographic
data were analyzed with multisample comparison ANOVA with
post hoc Bonferonni corrections. A value of P o 0.05 was
considered statistically signiﬁcant.Results
Beneﬁcial effects of sRAGECHO treatment measured by vessel
ultrasound sonography 1 to 2 weeks after the injury
Our previous studies21 had demonstrated that administration of
sRAGE immediately after arterial injury is most therapeutically
effective. To monitor sRAGECHO effects in live rats with carotid
arterial injury, we performed the ultrasound sonography procedure
on rats before the surgery, and at 1 and 2 weeks postsurgery.
Although at 1 week postsurgery the maximal vessel lumen diameter
of injured vessels treated by sRAGECHO is clearly distinguishable
from that of placebo-treated vessels (Figure 1A), the measurement of
average vessel wall thickness of these 2 groups was not clearly
differentiated until 2 weeks postsurgery (Figure 1B), suggesting that
sufﬁcient time (ie, at least 1 week) is required to assess the beneﬁts
of sRAGECHO treatment in a live animal model.
Correlation of ultrasound sonography and histomorphologic analyses
To test the correlation of sonographic data with that obtained
from postmortem histologic measurement, we plotted the data
from the 2 independent measurements, using the lowest effective
dose (ie, 0.5 ng/g body weight). Despite the shrinkage of vessel
cross-sections during the histologic process, reasonably high
correlations between the data from the 2 measurements were
apparent in the scatter plots (lumen diameter: R ¼ 0.72; vessel
wall thickness: R ¼ 0.76) (Figure 2A and 2B), suggesting that the
effect of sRAGECHO treatment can be independently, and perhaps
reliably monitored in vivo (Figure 2C).
Vessel sonographic assessment in rats treated with different sRAGE
doses and sRAGE produced from different cells
On the basis of timing and correlation with histologic results
shown in Figures 1 and 2, we also measured lumen diameter and
vessel wall thickness at 2 weeks postsurgery in rats treated with
sRAGECHO at lower (0.5–1.5 ng/g body weight) (Figure 3A and 3B)
and higher doses (1.5–6 ng/g body weight) (Figure 3C and 3D).
When vessel wall thickness was measured, 1.5 ng/g and higher
doses of sRAGECHO treatment appeared to be statistically similar to
those of nonoperated vessels (Figure 3A and 3C). However when
lumen diameter was measured, dose-dependent improvement in
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Figure 1. Observation of soluble receptor for advanced glycation end products (sRAGE) effects using vessel ultrasound sonography during 2 weeks of postarterial injury.
(A) Maximal lumen diameter during the 2 weeks postinjury. (B) The average vessel wall thickness during the 2 weeks postinjury. Empty circle ¼ nonoperated; ﬁlled square
¼ balloon-injured and sRAGE-treated; empty square ¼ balloon-injured and placebo-treated. Values are means (SEM); sRAGE administered ¼ 0.5 ng/g body weight. a ¼ P o
0.05 sRAGE Chinese hamster ovary-treated samples versus nonoperated; b ¼ P o 0.05 sRAGE Chinese hamster ovary-treated samples versus placebo-treated samples.
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(Figure 3B and 3D), suggesting that the latter parameter may be
more sensitive.Non-
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Figure 3. Soluble receptor for advanced glycation end products produced in Chinese hamster ovary (sRAGECHO) cells efﬁcacy measured by vessel ultrasound sonography. (A
and B) Low dose range (0.51.5 ng/g) of sRAGECHO treatment measured by sonography. (C and D) high does range (1.56 ng/g) of sRAGECHO treatment measured by
sonography. (A and C) Average wall thickness. (B and D) Average lumen diameter. Nonoperated: n ¼ 15; placebo-treated: n ¼ 15; dose 0.5–1.5, 6 ng/g: n ¼ 6; dose 3 ng/g: n
¼ 7. #P o 0.05; ##P o 0.01, nonoperated versus placebo and each dose group; *P o 0.05 and **P o 0.01 for placebo versus each dose group.
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therapeutic efﬁcacy of sRAGE. Independent assessment using sonog-
raphy (Figure 4) with an established optimal dose of sRAGECHO
further conﬁrmed a signiﬁcantly higher efﬁcacy of sRAGECHO relative
to that of nonglycosylated sRAGE (N25T/N81T) and sRAGE produced
in insect Sf9 cells.Discussion
The therapeutic value of sRAGE has been well recognized and
tested in various animal models, including arterial injury mod-
els.17,18,21,22 Administration of sRAGE, a decoy of RAGE, can reduce
injury-associated, RAGE signal-mediated chronic inﬂammation
and minimize maladaptation and remodeling in vasculature, thus
decreasing the risk of cardiovascular diseases and other vessel-0.35
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Figure 4. Modulation of soluble receptor for advanced glycation end products (sRAGE)
(A) Average wall thickness. (B) Average lumen diameter. Dose used in the studies ¼ 3
hamster ovary cells (CHO): n ¼ 7; sRAGESf9 and sRAGECHO(N25T/N81T): n ¼ 6. #P o
placebo versus each sRAGE group.associated complications. Although previous studies discovered
that sRAGE can be used to block neointimal growth and formation
of atherosclerotic plaques in animal models, to achieve the block-
age, a high dose and multiple administrations of sRAGE produced
in insect Sf9 cells were employed.17–19,26,27 Our recent study21
demonstrated that speciﬁc N-glycoform modiﬁcations are the key
determinant underlying sRAGE bioactivity and therapeutic efﬁ-
cacy: a low, single dose of sRAGE produced in CHO cells can
signiﬁcantly reduce injury-associated inﬂammation and neointi-
mal growth. In addition to the observed low efﬁcacy, glycoforms
from insect cells are also immunogenic in mammals, and ther-
apeutic glycoproteins must be produced from mammalian sources.
Previous studies, including ours, had evaluated therapeutic
effects of sRAGE mainly based on postmortem histomorphologic
analyses of the vessel cross-sections and in vitro bioactivity
assays. Although these assessments, especially histologic studies,B
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efﬁcacy via N-glycoform modiﬁcation measured by vessel ultrasound sonography.
ng/g. Nonoperated: n ¼ 15; placebo-treated: n ¼ 15; sRAGE produced in Chinese
0.05, ##P o 0.01, nonoperated versus placebo and each sRAGE group; **P o 0.01,
H.-J. Tae et al. / Current Therapeutic Research 76 (2014) 110–115114provided important and direct information of the vessel condition,
including inﬂammation and formation of the neointima, these
approaches cannot be used for clinical evaluation of treatment.
The present study demonstrates that injury of the vessel as well as
the therapeutic effects of sRAGECHO can be independently evaluated
via vessel sonographic assessment. Similar to the results obtained
from histology shown in our previous study,21 current sonographic
studies also showed a degree of dose-dependent attenuation of vessel
lumen diameter, although this was less apparent in measured vessel
wall thickness (Figure 3). Consistent with histology,21 sonography also
showed that paucimannose-glycan modiﬁed sRAGESf9 and the non-
glycosylated sRAGECHO(N25T/N81T) were ineffective when used in
the same dose (3 ng/g) as sRAGECHO (Figure 4). Previous studies17,21
showed that sRAGECHO administered immediately after arterial injury
was most effective to restrict neointimal expansion. The manifested
beneﬁcial effects of sRAGECHO are not readily detectable in vivo until
at least 1 week after surgery and treatment, and the therapeutic
outcome becomes apparent 2 weeks after surgery and treatment
(Figure 1). These observations suggest that blocking RAGE alarmin
ligands immediately after injury circumvents RAGE-mediated inﬂam-
matory signaling, and allows the injured vessel to undergo a repair
process with less, or controlled, inﬂammation leading to a healing
course with reduced remodeling. Compared with our previously
published histology results,21 vessel ultrasound sonography appears
to be less sensitive to discern the difference between nonoperated
vessels and vessels operated onwith treatment when a higher dose of
sRAGECHO (3 ng/g) was used (Figure 4A), whereas such difference was
discernable by histology. When a lower dose of sRAGECHO was used
(0.5 ng/g), the difference between treated and nonoperated vessels is
clearly discernable and there was a better correlation between
sonography and histology (Figure 2). This is likely due to the fact
that 0.5 ng/g is not an optimal dose, and that remodeling of the vessel
wall by balloon denudation was not suppressed as much as that in a
situation when a higher dose was administered. These observations
suggest that sonographic data should serve as a reference for
application, and that the exaggerated beneﬁts observed in higher
sRAGE doses should be taken into consideration to determine a
proper dose for the best treatment outcome.Conclusions
Our research using vessel sonography to monitor sRAGE effects
in live rats reafﬁrmed that speciﬁc N-glycoform-modiﬁed sRAGE,
produced in CHO cells is highly effective in vivo to attenuate
neointimal growth after arterial injury, compared with that
produced in insect cells. This in vivo approach also provides a
basis for monitoring sRAGE effects in future clinical applications.Acknowledgments
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